TerminatedPHASE1, PHASE2NCT01100944
A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies
Studying Thymoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Arun Rajan, M.D., M.DNational Cancer Institute (NCI)
- Intervention
- PXD101with cisplatin+doxorubicin+cyclophosphamide(drug)
- Enrollment
- 26 enrolled
- Eligibility
- 18-100 years · All sexes
- Timeline
- 2010 – 2015
Study locations (1)
- National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01100944 on ClinicalTrials.govOther trials for Thymoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06730308Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable ThymomaSun Yat-sen University
- RECRUITINGNANCT06029621Robot-assisted vs VATS for ThymomaShanghai Pulmonary Hospital, Shanghai, China
- ACTIVE NOT RECRUITINGNANCT05682742Clinical Investigation of the da Vinci Surgical SystemIntuitive Surgical
- RECRUITINGNANCT02633553Adjuvant Radiotherapy for Stage II/III Thymoma After Complete ResectionFudan University
- ACTIVE NOT RECRUITINGPHASE2NCT03076554A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based ChemotherapyNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGNANCT03968315An Investigational Scan (MRI) in Imaging Patients With Newly-Diagnosed or Recurrent ThymomaM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT01025089Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic CarcinomaMemorial Sloan Kettering Cancer Center